Rocket Pharmaceuticals (RCKT) Competitors $3.28 -0.07 (-2.09%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.28 0.00 (0.00%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RCKT vs. EWTX, SDGR, AVDL, ARDX, JANX, HROW, VERA, AMPH, SNDX, and ETNBShould you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Edgewise Therapeutics (EWTX), Schrodinger (SDGR), Avadel Pharmaceuticals (AVDL), Ardelyx (ARDX), Janux Therapeutics (JANX), Harrow (HROW), Vera Therapeutics (VERA), Amphastar Pharmaceuticals (AMPH), Syndax Pharmaceuticals (SNDX), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry. Rocket Pharmaceuticals vs. Its Competitors Edgewise Therapeutics Schrodinger Avadel Pharmaceuticals Ardelyx Janux Therapeutics Harrow Vera Therapeutics Amphastar Pharmaceuticals Syndax Pharmaceuticals 89BIO Edgewise Therapeutics (NASDAQ:EWTX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Is EWTX or RCKT more profitable? Edgewise Therapeutics' return on equity of -30.65% beat Rocket Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Edgewise TherapeuticsN/A -30.65% -29.18% Rocket Pharmaceuticals N/A -65.11%-55.99% Which has more risk and volatility, EWTX or RCKT? Edgewise Therapeutics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Do analysts rate EWTX or RCKT? Edgewise Therapeutics presently has a consensus target price of $40.55, suggesting a potential upside of 182.55%. Rocket Pharmaceuticals has a consensus target price of $16.73, suggesting a potential upside of 410.16%. Given Rocket Pharmaceuticals' higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Edgewise Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91Rocket Pharmaceuticals 1 Sell rating(s) 8 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.41 Which has preferable earnings and valuation, EWTX or RCKT? Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdgewise TherapeuticsN/AN/A-$133.81M-$1.55-9.26Rocket PharmaceuticalsN/AN/A-$258.75M-$2.51-1.31 Does the media refer more to EWTX or RCKT? In the previous week, Edgewise Therapeutics had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 9 mentions for Edgewise Therapeutics and 8 mentions for Rocket Pharmaceuticals. Edgewise Therapeutics' average media sentiment score of 1.09 beat Rocket Pharmaceuticals' score of 0.96 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in EWTX or RCKT? 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 23.2% of Edgewise Therapeutics shares are held by insiders. Comparatively, 24.8% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryEdgewise Therapeutics beats Rocket Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Rocket Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCKT vs. The Competition Export to ExcelMetricRocket PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$353.93M$3.07B$5.75B$9.76BDividend YieldN/A2.29%4.10%4.04%P/E Ratio-1.3120.7883.2726.59Price / SalesN/A386.79535.03111.31Price / CashN/A44.2237.4459.26Price / Book1.008.0710.556.58Net Income-$258.75M-$53.98M$3.27B$265.95M7 Day Performance-9.89%-0.88%0.40%0.17%1 Month Performance7.54%7.72%7.31%3.90%1 Year Performance-82.60%7.03%46.58%19.67% Rocket Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCKTRocket Pharmaceuticals4.9013 of 5 stars$3.28-2.1%$16.73+410.2%-82.6%$353.93MN/A-1.31240EWTXEdgewise Therapeutics2.3256 of 5 stars$14.30-3.7%$40.55+183.5%-23.5%$1.56BN/A0.0060Insider TradeSDGRSchrodinger3.1294 of 5 stars$19.54-3.8%$27.83+42.4%-7.2%$1.50B$207.54M-7.88790Positive NewsAnalyst DowngradeAVDLAvadel Pharmaceuticals2.9885 of 5 stars$14.81-2.8%$19.67+32.8%-2.7%$1.48B$169.12M-493.6770News CoverageARDXArdelyx4.0845 of 5 stars$6.06-0.8%$11.50+89.8%+2.9%$1.47B$333.61M-26.3590News CoverageInsider TradeJANXJanux Therapeutics2.6669 of 5 stars$23.01-5.3%$86.90+277.7%-51.6%$1.46B$10.59M0.0030News CoveragePositive NewsHROWHarrow3.3803 of 5 stars$37.36-4.5%$64.67+73.1%-3.6%$1.45B$199.61M0.00180VERAVera Therapeutics3.766 of 5 stars$21.34-5.4%$63.00+195.2%-42.8%$1.44BN/A0.0040News CoveragePositive NewsAMPHAmphastar Pharmaceuticals3.2972 of 5 stars$29.83-2.2%$31.50+5.6%-37.2%$1.42B$731.97M11.172,028Positive NewsAnalyst ForecastSNDXSyndax Pharmaceuticals3.8536 of 5 stars$15.66-3.6%$38.00+142.7%-20.5%$1.40B$23.68M0.00110Positive NewsETNB89BIO2.2978 of 5 stars$9.10-3.5%$26.63+192.6%-4.9%$1.40BN/A0.0040News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies EWTX Competitors SDGR Competitors AVDL Competitors ARDX Competitors JANX Competitors HROW Competitors VERA Competitors AMPH Competitors SNDX Competitors ETNB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RCKT) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCKT Stock Alerts